Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 51, 2021 - Issue 7
189
Views
1
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Hypothesis of using albumin to improve drug efficacy in cancers accompanied by hypoalbuminemia

ORCID Icon &
Pages 778-785 | Received 03 Mar 2021, Accepted 08 May 2021, Published online: 25 May 2021
 

Abstract

  1. A common problem in many cancers is the resistance of some patients to common drugs or relapse. Hypoalbuminemia has been reported in some of resistant cancer patients.

  2. This article evaluates the usefulness of albumin in the treatment of drug-resistant cancers with hypoalbuminemia based on available evidences.

  3. Rapid metabolism and drug excretion from the body is one of the causes of drug resistance. Albumin is the major plasma protein to which almost all drugs are bound. There is some evidence that increasing drug binding to albumin has beneficial effects on drug efficacy in some cancers and cancer cells. On the other hand, some reports have shown that cancer cells can use albumin as the energy and amino acid source.

  4. We have hypothesized that in this particular group of cancers, adding albumin to a treatment regimen could have a beneficial effect on drug efficacy and dosage. In fact, excess albumin can prevent rapid metabolism of drug by increasing the fraction of albumin-bound drug, and can increase drug delivery to cancer cells due to the absorption of drug-albumin complex by cancer cells.

Acknowledgements

The authors thank the Vice Chancellor for Research and Technology, Kermanshah University of Medical Sciences for providing the conditions for conducting this research, and the colleagues of the Medical Biology Research Center, especially Dr. Amir Hossein Norooznezhad, for their helpful comments.

Disclosure statement

The authors report no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.